Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction
Abstract
:1. Introduction
2. Results
3. Discussion
4. Conclusions
5. Materials and Methods
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hamid, R.; Averbeck, M.A.; Chiang, H.; Garcia, A.; Al Mousa, R.T.; Oh, S.J.; Patel, A.; Plata, M.; Del Popolo, G. Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. World J. Urol. 2018, 36, 1517–1527. [Google Scholar] [CrossRef]
- Mahfouz, W.; Corcos, J. Management of detrusor external sphincter dyssynergia in neurogenic bladder. Eur. J. Phys. Rehabil. Med. 2011, 47, 639–650. [Google Scholar] [PubMed]
- Myers, J.B.; Lenherr, S.M.; Stoffel, J.T.; Elliott, S.P.; Presson, A.P.; Zhang, C.; Rosenbluth, J.; Jha, A.; Patel, D.P.; Welk, B.; et al. Patient Reported Bladder Related Symptoms and Quality of Life after Spinal Cord Injury with Different Bladder Management Strategies. J. Urol. 2019, 202, 574–584. [Google Scholar] [CrossRef]
- Perkash, I. Transurethral sphincterotomy provides significant relief in autonomic dysreflexia in spinal cord injured male patients: Long-term follow up results. J. Urol. 2007, 177, 1026–1029. [Google Scholar] [CrossRef] [PubMed]
- Ahmed, H.U.; Shergill, I.S.; Arya, M.; Shah, P.J.R. Management of detrusor-external sphincter dyssynergia. Nat. Clin. Pract. Urol. 2006, 3, 368–380. [Google Scholar] [CrossRef]
- Dykstra, D.D.; Sidi, A.A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study. Arch. Phys. Med. Rehabil. 1990, 71, 24–26. [Google Scholar]
- Schurch, B.; Hauri, D.; Rodic, B.; Curt, A.; Meyer, M.; Rossier, A.B. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: A prospective study in 24 spinal cord injury patients. J. Urol. 1996, 155, 1023–1029. [Google Scholar] [CrossRef]
- Dykstra, D.D.; Sidi, A.A.; Scott, A.B.; Pagel, J.M.; Goldish, D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. 1988, 139, 919–922. [Google Scholar] [CrossRef]
- Liao, Y.M.; Kuo, H.C. Causes of failed urethral botulinum toxin A treatment for emptying failure. Urology 2007, 70, 763–766. [Google Scholar] [CrossRef] [PubMed]
- Kuo, H.C. Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia. Int. J. Clin. Pract. 2013, 67, 1044–1049. [Google Scholar] [CrossRef]
- Kuo, H.C. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J. Urol. 2003, 170, 1908–1912. [Google Scholar] [CrossRef]
- Franks, M.W.; Franks, M.; Somogyi, G.T.; Yokoyama, T.; Fraser, M.O.; Lavelle, J.P.; Yoshimura, N.; Chancellor, M.B. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J. Urol. 2001, 165, 1107–1110. [Google Scholar]
- Mehta, S.; Hill, D.; Foley, N.; Hsieh, J.; Ethans, K.; Potter, P.; Baverstock, R.; Teasell, R.W.; Wolfe, D.; Spinal Cord Injury Rehabilitation Evidence Research Team. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch. Phys. Med. Rehabil. 2012, 93, 597–603. [Google Scholar] [CrossRef] [PubMed]
- de Sèze, M.; Petit, H.; Gallien, P.; de Sèze, M.P.; Joseph, P.A.; Mazaux, J.M.; Barat, M. Botulinum a toxin and detrusor sphincter dyssynergia: A double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur. Urol. 2002, 42, 56–62. [Google Scholar] [CrossRef]
- Kuo, H.C. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol. Urodyn. 2008, 27, 793–796. [Google Scholar] [CrossRef]
- Smith, C.P.; Nishiguchi, J.; O’Leary, M.; Yoshimura, N.; Chancellor, M.B. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005, 65, 37–41. [Google Scholar] [CrossRef]
- Gallien, P.; Reymann, J.-M.; Amarenco, G.; Nicolas, B.; de Sèze, M.; Bellissant, E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J. Neurol. Neurosurg. Psychiatry 2005, 76, 1670–1676. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Mahfouz, W.; Karsenty, G.; Corcos, J. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: Review of indications, techniques and results: 2011 update. Can. J. Urol. 2011, 18, 5787–5795. [Google Scholar] [PubMed]
- Schulte-Baukloh, H.; Weiss, C.; Stolze, T.; Herholz, J.; Stürzebecher, B.; Miller, K.; Knispela, H.H. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: Objective outcome and patient satisfaction. Eur. Urol. 2005, 48, 984–990. [Google Scholar] [CrossRef]
- Chen, Y.H.; Kuo, H.C. Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions. Urol. Int. 2004, 73, 156–161. [Google Scholar] [CrossRef]
- Leippold, T.; Reitz, A.; Schurch, B. Botulinum toxin as a new therapy option for voiding disorders: Current state of the art. Eur. Urol. 2003, 44, 165–174. [Google Scholar] [CrossRef]
- Chen, S.L.; Bih, L.I.; Huang, Y.H.; Tsai, S.J.; Lin, T.B.; Kao, Y.L. Effect of single botulinum toxin A injection to the external urethral sphincter for treating detrusor external sphincter dyssynergia in spinal cord injury. J. Rehabil. Med. 2008, 40, 744–748. [Google Scholar] [CrossRef][Green Version]
- Soler, J.M.; Previnaire, J.G.; Hadiji, N. Predictors of outcome for urethral injection of botulinum toxin to treat detrusor sphincter dyssynergia in men with spinal cord injury. Spinal Cord. 2016, 54, 452–456. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Y.H.; Jhang, J.F.; Chen, S.F.; Kuo, H.C. Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. Low Urin. Tract Symptoms 2019, 11, 66–71. [Google Scholar] [CrossRef] [PubMed]
- Weld, K.J.; Graney, M.J.; Dmochowski, R.R. Clinical significance of detrusor sphincter dyssynergia type in patients with post-traumatic spinal cord injury. Urology 2000, 56, 565–568. [Google Scholar] [CrossRef]
- Schurch, B. Neurogenic voiding disorders. Current status of diagnosis and therapy. Schweiz Med. Wochenschr. 2000, 130, 1618–1626. [Google Scholar] [PubMed]
- Abrams, P.; Cardozo, L.; Fall, M.; Griffiths, D.; Rosier, P.; Ulmsten, U.; van Kerrebroeck, P.; Victor, A.; Wein, A.; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the international continence society. Neurourol. Urodyn. 2002, 21, 167–178. [Google Scholar] [CrossRef]
N | Not Improved | Mildly Improved | Moderately Improved | Markedly Improved | p Value * | |
---|---|---|---|---|---|---|
Total | 118 | 8 (6.8%) | 39 (33.1%) | 53 (44.9%) | 18(15.3%) | |
Male Female | 94 24 | 8 (8.5%) 0 | 31 (33.0%) 8 (33.3%) | 39 (41.5%) 14 (58.3%) | 16 (17.0%) 2 (8.3%) | 0.288 |
Level of SCI Cervical Thoracic Lumbo-sacral | 51 43 24 | 4 (7.8%) 3 (7.0%) 1 (4.2%) | 13 (25.5%) 16 (37.2%) 10 (41.7%) | 25 (49.0%) 18 (41.9%) 10 (41.7%) | 9 (17.6%) 6 (14.0%) 3 (12.5%) | 0.866 |
NDO-DSD NDO + AD + DSD NDO + DSD DA + DSD DA+ ISD | 5 57 25 30 1 | 0 4 (7.0%) 1 (4.0%) 3 (10.0%) 0 | 3 (60.0%) 16 (28.1%) 6 (24.0%) 14 (46.7%) 0 | 0 32 (56.1%) 11 (44.0%) 9 (30.0%) 1 (100%) | 2 (40.0%) 5 (8.8%) 7 (28.0%) 4 (13.3%) 0 | 0.052 |
With AD Non-AD | 87 31 | 5 (5.7%) 3 (9.7%) | 31 (35.6%) 8 (25.8%) | 41 (47.1%) 12 (38.7%) | 10 (11.5%) 8 (25.8%) | 0.190 |
Hand function Normal Partial Incapable | 89 15 14 | 6 (6.7%) 0 2 (14.3%) | 33 (37.1%) 3 (20.0%) 3 (21.4%) | 40 (44.9%) 7 (46.7%) 6 (42.9%) | 10 (11.2%) 5 (33.3%) 3 (21.4%) | 0.199 |
Complete Incomplete | 80 38 | 7 (8.8%) 1 (2.6%) | 28 (35.0%) 11 (28.9%) | 33 (41.3%) 20 (52.6%) | 12 (15.0%) 6 (15.8%) | 0.482 |
Urodynamic Parameters | Not Improved | Mildly Improved | Moderately Improved | Markedly Improved | p Value |
---|---|---|---|---|---|
Patient no. | 8 (6.8%) | 39 (33.1%) | 53 (44.9%) | 18 (15.3%) | |
Age | 49.2 ± 17.3 | 48.2 ± 14.8 | 46.5 ± 18.4 | 50.4 ± 15.2 | 0.842 |
Duration | 6.8 ± 8.0 | 8.3 ± 11.1 | 5.2 ± 8.9 | 6.4 ±10.8 | 0.570 |
FSF (mL) | 148 ± 48.6 | 176 ± 110 | 133 ± 67.1 | 143 ± 94.3 | 0.140 |
FS (mL) | 214 ± 117 | 249 ± 120 | 195 ± 96.0 | 235 ± 139 | 0.151 |
US (mL) | 237 ± 125 | 280 ± 139 | 220 ± 110 | 281 ± 160 | 0.113 |
Compliance | 24.2 ± 18.6 | 69.0 ± 82.2 | 40.5 ± 57.7 | 61.6 ± 82.1 | 0.147 |
Pdet (cmH2O) | 38.5 ± 32.6 | 33.7 ± 20.5 | 35.8 ± 23.7 | 24.4 ± 17.1 | 0.038 |
Qmax (mL/s) | 2.75 ± 5.26 | 3.64 ± 4.59 | 3.83 ± 3.96 | 2.78 ± 4.05 | 0.775 |
Volume (mL) | 136 ± 166 | 73.3 ± 144 | 60.5 ± 80.6 | 31.8 ± 50.4 | 0.084 |
PVR (mL) | 232 ± 153 | 281 ± 216 | 218 ± 148 | 285 ± 195 | 0.316 |
VE (%) | 32.6 ± 41.1 | 25.1 ± 31.6 | 25.6 ± 29.5 | 16.1 ± 25.1 | 0.570 |
BCI | 52.3 ± 43.4 | 42.0 ± 30.6 | 54.9 ± 29.0 | 38.3 ± 31.0 | 0.115 |
BOOI | 33.0 ± 33.5 | 16.5 ± 22.5 | 28.1 ± 25.8 | 18.9 ± 16.0 | 0.074 |
N | Not Improved | Mildly Improved | Moderately Improved | Markedly Improved | p Value | |
---|---|---|---|---|---|---|
Self-voiding and on medication | 55 | 4 (7.3%) | 16 (29.1%) | 28 (50.9%) | 7 (12.7%) | 0.472 |
Urethral BoNT-A | 42 | 16 (38.1%) | 14 (33.3%) | 10 (23.8%) | 2 (4.8%) | 0.915 |
Detrusor BoNT-A/CIC | 20 | 1 (5.0%) | 6 (30.0%) | 10 (50.0%) | 3 (15.0%) | 0.628 |
AE and CIC | 5 | 0 | 2 (40%) | 1 (20.0%) | 2 (40%) | 1.000 |
TUI-BN | 16 | 1 (6.3%) | 10 (62.5%) | 4 (25.0%) | 1 (6.3%) | 0.011 |
TUI-P/TUR-P | 9 | 0 | 3 (33.3%) | 4 (44.4%) | 2 (22.2%) | 1.000 |
Suburethral sling | 2 | 0 | 1 (50.0%) | 1 (50.0%) | 0 | 1.000 |
Cystostomy | 2 | 0 | 1 (25.0%) | 3 (75.0%) | 0 | 0.157 |
Indwelling catheter | 4 | 0 | 3 (75.0%) | 1 (25.0%) | 0 | 1.000 |
CIC alone | 10 | 1 (10.0%) | 4 (40.0%) | 5 (50.0%) | 0 | 0.517 |
External sphincterotomy | 5 | 2 (40.0%) | 1 (20.0%) | 1 (20.0%) | 1 (20.0%) | 0.386 |
N | Very Satisfied | Satisfied but Wish to Change | Unsatisfied but No Change | Very Unsatisfied | p Value * | |
---|---|---|---|---|---|---|
118 | 40 (33.9%) | 30 (25.4%) | 41 (41.7%) | 7 (5.9%) | ||
Level of SCI Cervical Thoracic Lumbo-sacral | 51 43 24 | 17 (33.3%) 17 (39.5%) 6 (25.0%) | 13 (25.5%) 12 (27.9%) 5 (20.8%) | 18 (35.3%) 13 (30.2%) 10 (41.7%) | 3 (5.9%) 1 (2.3%) 3 (12.5%) | 0.630 |
Self-voiding and on medication | 55 | 16 (29.1%) | 12 (21.8%) | 23 (41.8%) | 7 (7.3%) | 0.395 |
Urethral BoNT-A | 42 | 16 (38.1%) | 14 (33.3%) | 10 (23.8%) | 2 (4.8%) | 0.228 |
Detrusor BoNT-A/CIC | 20 | 7 (35.0%) | 7 (35.0%) | 5 (25.0%) | 1 (5.0%) | 0.666 |
AE and CIC | 5 | 4 (80.0%) | 0 | 1 (20.0%) | 0 | 0.249 |
TUI-BN | 16 | 10 (62.5%) | 4 (25.0%) | 2 (12.5%) | 0 | 0.051 |
TUI-P/ TUR-P | 9 | 2 (22.2%) | 4 (44.4%) | 3 (33.3%) | 0 | 0.560 |
Suburethral sling | 2 | 2 (100%) | 0 | 0 | 0 | 0.292 |
Cystostomy | 2 | 0 | 0 | 2 (100%) | 0 | 0.410 |
Indwelling catheter | 4 | 0 | 3 (75.0%) | 1 (25.0%) | 0 | 0.165 |
CIC alone | 10 | 5 (50.0%) | 1 (10.0%) | 3 (30.0%) | 1 (10.0%) | 0.394 |
External sphincterotomy | 5 | 2 (40.0%) | 1 (20.0%) | 2 (40.0%) | 0 | 1.000 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, C.-L.; Jhang, J.-F.; Jiang, Y.-H.; Kuo, H.-C. Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction. Toxins 2022, 14, 30. https://doi.org/10.3390/toxins14010030
Lee C-L, Jhang J-F, Jiang Y-H, Kuo H-C. Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction. Toxins. 2022; 14(1):30. https://doi.org/10.3390/toxins14010030
Chicago/Turabian StyleLee, Cheng-Ling, Jia-Fong Jhang, Yuan-Hong Jiang, and Hann-Chorng Kuo. 2022. "Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction" Toxins 14, no. 1: 30. https://doi.org/10.3390/toxins14010030